Professional Background:

Since joining ANSTO in 2000 as a postdoctoral research fellow, Ivan has been a key player in the field of radiochemistry. His expertise lies in the development of diagnostic radiopharmaceuticals using F-18, Tc-99m, and I-123 radioisotopes. In 2003, he was appointed as a Radiochemist and, in 2010, he took on the role of Head of Radiochemistry. In this capacity, Ivan has successfully managed a team of radioisotope and radiopharmaceutical scientists, overseeing the delivery of technologies and products to institutional, academic and industry partners.

Research Interests:

Ivan leads a team of radiochemistry scientists at ANSTO. Team research interests include advanced manufacture, radioisotope separations, and theranostic radiopharmaceuticals. The aim of the team is to develop and translate radioisotopes and radiopharmaceuticals for preclinical and clinical evaluation. These research themes primarily utilise therapeutic radioisotopes from the OPAL research reactor, e.g., Lu-177, Tb-161, and I-131, with plans to expand the set of radioisotopes. The research programs intend to develop sovereign radiochemistry capability to support clinical researchers and ANSTO’s nuclear medicine business.